Valuation — not yet established
No valuation for Aktis Oncology is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($336.0M) and the funding record below are the closest available signals.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for Aktis Oncology
Create free account
No card required
Funding history
1 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Sep 2024 | Early Stage VC (Series B) | $175.0M | ▮ | ▮ |
How Aktis Oncology's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Aktis Oncology, we compose those signals into the PA Mark — a weighted composite of 1 recent pricing inputs, decayed by age and reset on new rounds. The implied valuation multiplies the mark by shares outstanding. Full methodology →
Frequently asked
- How much has Aktis Oncology raised?
- Aktis Oncology has raised $336.0M in total funding across 1 recorded rounds.
- When did Aktis Oncology last raise?
- Aktis Oncology last raised in Sep 2024 (Early Stage VC (Series B)), raising $175.0M.